Management of Diffuse Liver Parenchymal Disease

Initial Diagnostic Imaging

The American College of Radiology recommends abdominal ultrasound as the mandatory first-line imaging modality for evaluating diffuse liver parenchymal disease due to its portability, cost-effectiveness, and ability to detect key pathological features 1
Ultrasound findings to evaluate include diffuse hepatic hypoechogenicity indicating acute hepatic parenchymal inflammation, increased thickness of portal vein walls, "starry sky" appearance, contracted gallbladder with wall thickening and edema, and liver size and contour abnormalities suggesting chronicity 1
The American College of Radiology suggests adding Duplex Doppler to the grayscale ultrasound to assess vascular patency, particularly when ischemic injury is suspected 1

MRI with IV contrast should be obtained when ultrasound findings are equivocal or when detailed assessment of parenchymal inflammation, perfusion, and vascular patency is needed, according to the American College of Radiology 1
MRI findings to evaluate include increased T2 signal intensity and decreased T1 signal indicating inflamed liver parenchyma, periportal edema, heterogeneous arterial phase enhancement, perihepatic fluid and gallbladder wall edema, and non-enhancing wedge-shaped areas indicating hepatic infarction 1

Laboratory testing must be directed by the pattern of liver enzyme elevation, with the American Association for the Study of Liver Diseases recommending viral hepatitis serologies, autoimmune markers, metabolic screening, and toxicology screen for hepatocellular pattern, and confirming hepatic origin with GGT for cholestatic pattern 1, 2, 3, 4

The American Association for the Study of Liver Diseases states that liver biopsy remains the reference standard for staging diffuse parenchymal disease when treatment decisions depend on fibrosis stage, with a minimum 2-3 cm length and 16-gauge caliber, and obtaining at least 11 complete portal tracts for accurate grading and staging 2, 5, 6
Transient elastography combined with serum biomarkers can reduce the need for biopsy in many cases, particularly for detecting advanced fibrosis or excluding minimal fibrosis, according to the American Association for the Study of Liver Diseases 6, 3

The American Association for the Study of Liver Diseases recommends prioritizing treatment for patients with F3-F4 fibrosis due to higher risk of complications, and initiating corticosteroid therapy based on histological confirmation for autoimmune hepatitis 2, 3, 7
For NAFLD/NASH, pharmacological treatment should be limited to biopsy-proven NASH with fibrosis, with a target 7-10% weight loss, reducing caloric intake by 30% or 750-1,000 kcal/day, and vigorous exercise (≥6 METs) required for fibrosis improvement, as recommended by the American Association for the Study of Liver Diseases 7

The American Association for the Study of Liver Diseases advises against performing percutaneous liver biopsy in patients with suspected hereditary hemorrhagic telangiectasia with liver vascular malformations, and avoiding NSAIDs in any patient with suspected cirrhosis due to risks of renal failure, GI bleeding, and hepatic decompensation 9, 10

Patients with cirrhosis require lifelong HCC surveillance with ultrasound every 6 months, even after successful treatment of underlying disease, as recommended by the American Association for the Study of Liver Diseases 3
Repeat staging should be considered when clinical status changes or when treatment decisions need reassessment, as single biopsies have sampling variability with 33% showing discordant results by at least one stage, according to the American Association for the Study of Liver Diseases 6